Abstract
The authors estimated the sample sizes needed for exploratory trials of MS assessing the efficacy of new treatments in reducing the number of new enhancing lesions vs those of interferon-β or glatiramer acetate. The sample sizes per arm ranged from 868 (effect: 20%) to 94 (effect: 50%) for patients with relapsing-remitting MS and from 2,484 (effect: 20%) to 361 (effect: 50%) for patients with secondary progressive MS. In MS, exploratory trials of new vs available therapies require large numbers of patients, even when MR end-points are used.
| Original language | English |
|---|---|
| Pages (from-to) | 1883-1885 |
| Number of pages | 3 |
| Journal | Neurology |
| Volume | 57 |
| Issue number | 10 |
| Publication status | Published - Nov 27 2001 |
Fingerprint
ASJC Scopus subject areas
- Neuroscience(all)
Cite this
Sormani, M. P., Rovaris, M., Bagnato, F., Molyneux, P., Bruzzi, P., Pozzilli, C., Miller, D. H., Comi, G., & Filippi, M. (2001). Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments. Neurology, 57(10), 1883-1885.